Navigation Links
Oramed Pharmaceuticals Appoints New Chief Operating Officer and VP of Business Development
Date:4/16/2013

JERUSALEM, April 16, 2013 /PRNewswire/ --

Oramed Pharmaceuticals Inc. (NASDAQCM: ORMP) (http://www.oramed.com), a developer of oral drug delivery systems, today announced a key addition to its executive leadership team with the appointment of Joshua Hexter as Chief Operating Officer and Vice President of Business Development.

"Josh will be a great addition and complement to Oramed's executive team as we enter a new era in our clinical trials and activities," commented Oramed CEO Nadav Kidron .  

Mr. Hexter brings to Oramed more than 15 years of prominent leadership with a commitment to excellence in the biotech industry in business development and operations. Most recently he was Executive Director of Corporate In-Licensing at BioLineRx (NASDAQ: BLRX). Mr. Hexter received his B.A. from the University of Wisconsin and his Masters in Business Management from Boston University.

 About Oramed Pharmaceuticals

Oramed Pharmaceuticals is a technology pioneer in the field of oral delivery solutions for drugs and vaccines currently delivered via injection. Established in 2006, Oramed's technology is based on over 30 years of research by top research scientists at Jerusalem's Hadassah Medical Center. Oramed is seeking to revolutionize the treatment of diabetes through its proprietary flagship product, an orally ingestible insulin capsule (ORMD-0801) currently approaching Phase 2 clinical trials under U.S. IND, and with its oral exenatide capsule (ORMD-0901; a GLP-1 analog), currently approaching Phase 2a trials. The company's corporate and R&D headquarters are based in Jerusalem.

The company's fact sheet can be viewed here.

For more information, the content of which is not part of this press release, please visit  http://www.oramed.com

Forward-looking statements: This press release contains forward-looking statements. For example, we are using forward-looking statements when we discuss our products approaching Phase 2 trials. These forward-looking statements are based on the current expectations of the management of Oramed only, and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements, including the risks and uncertainties related to the progress, timing, cost, and results of clinical trials and product development programs; difficulties or delays in obtaining regulatory approval or patent protection for our product candidates; competition from other pharmaceutical or biotechnology companies; and our ability to obtain additional funding required to conduct our research, development and commercialization activities. In addition, the following factors, among others, could cause actual results to differ materially from those described in the forward-looking statements: changes in technology and market requirements; delays or obstacles in launching our clinical trials; changes in legislation; inability to timely develop and introduce new technologies, products and applications; lack of validation of our technology as we progress further and lack of acceptance of our methods by the scientific community; inability to retain or attract key employees whose knowledge is essential to the development of our products; unforeseen scientific difficulties that may develop with our process; greater cost of final product than anticipated; loss of market share and pressure on pricing resulting from competition; laboratory results that do not translate to equally good results in real settings; our patents may not be sufficient; and final that products may harm recipients, all of which could cause the actual results or performance of Oramed to differ materially from those contemplated in such forward-looking statements. Except as otherwise required by law, Oramed undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. For a more detailed description of the risks and uncertainties affecting Oramed, reference is made to Oramed's reports filed from time to time with the Securities and Exchange Commission.

Company Contact:
Oramed Pharmaceuticals
Aviva Sherman
Cell: +972-54-792-4438
Office: +972-2-566-0001       
Email: aviva@oramed.com 



'/>"/>
SOURCE Oramed Pharmaceuticals Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Oramed Submits New IND Application for Oral Insulin Trial in the US
2. Oramed Pharmaceuticals Granted Japanese Patent for its Core Technology in Oral Delivery of Proteins
3. Oramed Pharmaceuticals to Present at the 4th Annual Drug Delivery & Formulation Summit in Berlin
4. Shares of Oramed Pharmaceuticals Are Approved for Listing on the Nasdaq Capital Market
5. Oramed Pharmaceuticals Inc. to Webcast, Live, at RetailInvestorConferences.com on February 7th
6. Oramed Pharmaceuticals Completes $5.6 Million Funding to Advance Clinical Trials
7. Oramed Pharmaceuticals to Present at the 12th Annual Diabetes Technology Society Meeting in Bethesda, MD, Nov 8-10, 2012
8. Oramed Pharmaceuticals Granted Core Technology Patent in New Zealand
9. Oramed Pharmaceuticals to Present at the 11th National Life Science & Technology Week ILSI-BIOMED Conference; Tel Aviv, Israel, 2012
10. Valeant Pharmaceuticals To Announce 2013 First Quarter Results On May 2, 2013
11. RoundTable Healthcare Partners and Argon Medical Devices Complete Acquisition of Angiotech Pharmaceuticals Interventional Products Business
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... Jan. 19, 2017 Accuray Incorporated (Nasdaq: ... TomoTherapy® Systems continue to set the bar for excellence ... composite overall user satisfaction rating among radiation treatment delivery ... MD Buyline Market Intelligence Briefing™. The most recent ratings ... ratings among industry peers for 11 of the past ...
(Date:1/19/2017)... , Jan. 19, 2017 ViewRay, Inc. (Nasdaq: ... federal institution supporting research in Germany ... patient treatments at the University Clinic Heidelberg as part ... The MRIdian Linac program will be headed by Medical ... heads radiation oncology at the German Cancer Research Center ...
(Date:1/19/2017)... -- New Review of Safinamide - ... and Motor Complications in Mid- to Late-stage Parkinson,s ... ... C Warren Olanow , ... 2-15, http://www.touchneurology.com/articles/safinamide-new-therapeutic-option-address-motor-symptoms-and-motor-complications-mid-late Published recently ...
Breaking Medicine Technology:
(Date:1/18/2017)... Charlottesville, Virginia (PRWEB) , ... January 18, 2017 , ... ... New studies are released almost daily linking gut health to chronic disease, mental health ... the New Year ” as an important resolution to consider. , For one Charlottesville ...
(Date:1/18/2017)... ... 2017 , ... The VA Maryland Health Care System and ... project focused on multiple sclerosis (MS). Led by Christopher M. Jewell, PhD, an ... disease without compromising normal immune function that often occurs during autoimmune diseases. Ultimately ...
(Date:1/18/2017)... ... January 18, 2017 , ... ... most-read publication among specialty pharmacists and pharmacy professionals, has teamed up with ... Partnership (SAP) program, announced Brian Haug, president of Pharmacy Healthcare Communications, LLC, ...
(Date:1/18/2017)... ... January 18, 2017 , ... A Palm Beach doctor plans to run the ... charity that provides free surgery to poor children suffering from cleft lip and cleft ... have run to support the efforts of the American Heart Association and the Leukemia ...
(Date:1/18/2017)... ... January 18, 2017 , ... The Portee Insurance Agency, a ... business owners in central Maryland and the DC region, is inaugurating a charity event ... people nationally every year, making it the #1 killer in America. However, heart disease ...
Breaking Medicine News(10 mins):